CollPlant Biotechnologies Ltd.
CLGNHealthcare|Biotechnology|IL
$3.97
+0.03 (+0.76%)
Tangible Book / Share
$2.01
Cash / Share
$2.05
Financials
Financial Snapshot
Market Cap
$7.5M
Enterprise Value
$7.2M
Revenue (TTM)
$318.0K
Net Income (TTM)
-$12.5M
Cash & Investments
$3.0M
Net Cash
$291.0K
Free Cash Flow (TTM)
-$11.7M
Operating CF (TTM)
-$11.6M
Debt/Equity
0.90
Cash Runway & Burn Rate
Cash on Hand
$3.0M
Quarterly Burn
$2.9M
Monthly Burn
$967.3K
Est. Runway
~1.0 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $987.1K | $5.1M | $5.3M | $3.8M | $3.3M | $43.3M | $29.7M | $26.7M | $11.9M | $6.0M | $3.0M | |
| Operating Cash Flow | -$5.0M | -$5.0M | -$1.2M | -$5.7M | -$4.5M | $2.5M | -$13.7M | -$2.8M | -$14.1M | -$9.4M | -$11.6M | |
| Free Cash Flow | -$5.2M | -$5.1M | -$2.0M | -$7.2M | -$4.9M | $1.1M | -$15.0M | -$3.7M | -$14.6M | -$9.4M | -$11.7M | |
| Capital Expenditure | -$127.7K | -$127.0K | -$832.0K | -$1.5M | -$437.0K | -$1.4M | -$1.3M | -$954.0K | -$483.0K | -$28.0K | -$94.0K | |
| Financing Cash Flow | $4.8M | $9.1M | $2.8M | $5.4M | $4.5M | $38.8M | $1.9M | $1.1M | $9.0K | $3.1M | $2.4M |
R&D Spending
R&D (TTM)
$6.9M
R&D Intensity
2173.6%
R&D Growth vs Prior
-15.6%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.9K | $479.9K | $4.8M | $2.3M | $6.1M | $15.6M | $299.0K | $11.0M | $515.0K | $2.4M | $318.0K | |
| R&D Expense | $4.4M | $4.0M | $5.2M | $4.4M | $3.7M | $7.6M | $10.3M | $10.5M | $10.5M | $8.2M | $6.9M | |
| R&D % of Revenue | 5749.7% | 843.3% | 107.8% | 190.4% | 59.6% | 48.8% | 3429.8% | 95.7% | 2041.7% | 345.3% | 2173.6% | |
| SG&A | $2.9M | $2.3M | $3.7M | $3.7M | $4.6M | $5.9M | $5.7M | $4.9M | $4.6M | $3.9M | $3.8M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.9K | $479.9K | $4.8M | $2.3M | $6.1M | $15.6M | $299.0K | $11.0M | $515.0K | $2.4M | $318.0K | |
| Cost of Revenue | $225.1K | $306.1K | $1.9M | $1.9M | $3.5M | $2.0M | $1.5M | $3.1M | $2.7M | $1.7M | $2.0M | |
| Gross Profit | -$149.0K | $157.6K | $3.1M | $439.0K | $2.7M | $13.6M | -$1.2M | $7.9M | -$2.1M | $624.0K | -$1.7M | |
| R&D | $4.4M | $4.0M | $5.2M | $4.4M | $3.7M | $7.6M | $10.3M | $10.5M | $10.5M | $8.2M | $6.9M | |
| SG&A | $2.9M | $2.3M | $3.7M | $3.7M | $4.6M | $5.9M | $5.7M | $4.9M | $4.6M | $3.9M | $3.8M | |
| Operating Income | -$7.2M | -$6.0M | -$4.1M | -$7.6M | -$5.6M | $65.0K | -$17.1M | -$7.5M | -$17.3M | -$11.5M | -$12.4M | |
| Interest Expense | $15.9K | $105.6K | $26.0K | $73.0K | $34.0K | $37.0K | $34.0K | $10.0K | $17.0K | $15.0K | $150.0K | |
| Pretax Income | -$7.3M | -$6.0M | -$3.7M | -$11.2M | -$5.8M | $237.0K | -$16.9M | -$7.0M | -$16.6M | -$11.5M | -$12.5M | |
| Net Income | -$7.3M | -$5.8M | -$6.2M | -$11.2M | -$5.8M | $237.0K | -$16.9M | -$7.0M | -$16.6M | -$11.5M | -$12.5M | |
| EPS (Diluted) | -36.00 | -22.70 | -14.30 | -29.50 | -8.40 | 0.34 | -15.20 | -6.20 | -14.50 | -9.40 | -9.39 | |
| EBITDA | -$7.0M | -$5.5M | -$5.9M | -$10.6M | -$5.1M | $1.0M | -$15.8M | -$5.9M | -$15.6M | -$10.6M | -$11.5M | |
| Shares Out. (M) | 0.20 | 0.27 | 0.44 | 0.50 | 0.69 | 1.20 | 1.10 | 1.14 | 1.15 | 1.22 | 1.44 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $987.1K | $5.1M | $5.3M | $3.8M | $3.3M | $13.1M | $29.7M | $26.7M | $11.9M | $6.0M | $3.0M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $30.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $2.1M | $6.4M | $7.1M | $5.0M | $5.7M | $45.1M | $31.7M | $28.0M | $13.2M | $6.7M | $3.9M | |
| Total Assets | $3.8M | $8.1M | $9.0M | $10.8M | $10.8M | $51.2M | $37.8M | $34.1M | $18.7M | $10.8M | $7.2M | |
| Total Current Liabilities | $1.8M | $1.4M | $2.2M | $3.5M | $3.4M | $3.0M | $3.1M | $3.3M | $3.0M | $2.7M | $2.5M | |
| Long-Term Debt | $0.00 | $3.6M | $22.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $2.4M | $5.5M | $4.3M | $6.7M | $6.4M | $6.1M | $5.5M | $5.8M | $5.2M | $4.7M | $4.3M | |
| Stockholders' Equity | $1.3M | $2.6M | $4.8M | $4.1M | $4.5M | $45.1M | $32.3M | $28.3M | $13.5M | $6.1M | $2.9M | |
| Retained Earnings | -$41.1M | -$50.2M | -$49.0M | -$67.3M | -$73.0M | -$72.8M | -$89.7M | -$96.7M | -$113.3M | -$124.8M | -$130.7M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.0M | -$5.0M | -$1.2M | -$5.7M | -$4.5M | $2.5M | -$13.7M | -$2.8M | -$14.1M | -$9.4M | -$11.6M | |
| Capital Expenditure | -$127.7K | -$127.0K | -$832.0K | -$1.5M | -$437.0K | -$1.4M | -$1.3M | -$954.0K | -$483.0K | -$28.0K | -$94.0K | |
| Free Cash Flow | -$5.2M | -$5.1M | -$2.0M | -$7.2M | -$4.9M | $1.1M | -$15.0M | -$3.7M | -$14.6M | -$9.4M | -$11.7M | |
| Investing Cash Flow | -$127.7K | -$127.0K | -$832.0K | -$1.5M | -$519.0K | -$31.6M | $28.9M | -$1.2M | -$539.0K | -$27.0K | -$8.9K | |
| Financing Cash Flow | $4.8M | $9.1M | $2.8M | $5.4M | $4.5M | $38.8M | $1.9M | $1.1M | $9.0K | $3.1M | $2.4M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $3.1M | $2.6M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $46.0K | -$20.0K | -$24.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $927.1K | $956.0K | $1.4M | $1.1M | $1.7M | $1.6M | $2.2M | $1.9M | $1.7M | $999.0K | $462.0K | |
| Net Change in Cash | -$379.0K | $4.3M | $379.0K | -$1.7M | -$445.0K | $9.8M | $16.5M | -$3.2M | -$14.8M | -$6.2M | -$8.8M |
Dilution Tracker
Shares outstanding grew 77.2% over 5 years — significant dilution
Shares Outstanding
2M
5-Year Share Growth
+77.2%
Stock Issuance (TTM)
$2.6M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.20 | 0.27 | 0.44 | 0.50 | 0.69 | 1.20 | 1.10 | 1.14 | 1.15 | 1.22 | 1.44 | |
| Change vs Prior % | — | 32.4% | 64.6% | 13.7% | 38.1% | 73.8% | -7.8% | 3.2% | 0.6% | 6.5% | 18.2% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $3.1M | $2.6M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $927.1K | $956.0K | $1.4M | $1.1M | $1.7M | $1.6M | $2.2M | $1.9M | $1.7M | $999.0K | $462.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -196.3% | 32.8% | 65.0% | 18.9% | 43.7% | 87.2% | -393.6% | 71.8% | -417.1% | 26.3% | -521.7% | |
| Operating Margin % | -9433.2% | -1244.2% | -84.9% | -329.2% | -91.2% | 0.4% | -5718.1% | -68.5% | -3349.7% | -484.3% | -3900.9% | |
| Net Margin % | -9571.9% | -1209.6% | -130.5% | -481.6% | -94.1% | 1.5% | -5660.5% | -64.0% | -3225.0% | -484.6% | -3934.9% | |
| EBITDA Margin % | -9255.1% | -1139.6% | -122.8% | -455.2% | -82.8% | 6.7% | -5289.3% | -53.9% | -3020.2% | -445.5% | -3621.7% | |
| FCF Margin % | -6786.7% | -1061.2% | -42.8% | -310.4% | -79.6% | 6.9% | -5007.4% | -33.9% | -2830.3% | -398.4% | -3679.6% | |
| ROE % | -541.7% | -222.1% | -131.3% | -273.1% | -129.0% | 0.5% | -52.4% | -24.8% | -123.3% | -188.9% | -215.6% | |
| ROA % | -193.7% | -71.9% | -69.1% | -103.8% | -53.3% | 0.5% | -44.8% | -20.6% | -88.8% | -106.5% | -173.9% | |
| ROIC % | -361.2% | -89.7% | -59.5% | -98.2% | -70.9% | 0.1% | -48.6% | -23.8% | -104.3% | -128.6% | -221.3% | |
| R&D / Revenue % | 5749.7% | 843.3% | 107.8% | 190.4% | 59.6% | 48.8% | 3429.8% | 95.7% | 2041.7% | 345.3% | 2173.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 532.2% | 897.8% | -51.6% | 164.8% | 154.9% | -98.1% | 3565.2% | -95.3% | 360.4% | |
| Gross Profit | 26.5% | 205.8% | 1874.2% | -85.9% | 510.3% | 409.0% | -108.6% | 768.3% | -127.3% | 129.1% | |
| Operating Income | -48.6% | 16.6% | 31.9% | -87.7% | 26.6% | 101.2% | -26403.1% | 56.1% | -129.6% | 33.4% | |
| Net Income | -51.4% | 20.1% | -7.7% | -78.7% | 48.3% | 104.1% | -7241.4% | 58.5% | -136.6% | 30.8% | |
| EPS (Diluted) | -27.2% | 36.9% | 37.0% | -106.3% | 71.5% | 104.1% | -4544.4% | 59.2% | -133.9% | 35.2% | |
| Operating Cash Flow | -35.0% | 1.2% | 75.5% | -368.6% | 22.0% | 156.2% | -647.7% | 79.8% | -410.1% | 33.2% | |
| Free Cash Flow | -26.4% | 1.1% | 59.8% | -251.1% | 32.1% | 122.0% | -1495.3% | 75.2% | -292.1% | 35.2% | |
| R&D Expense | 43.6% | -7.3% | 27.5% | -14.5% | -17.1% | 108.7% | 34.4% | 2.2% | 0.3% | -22.1% | |
| SG&A Expense | 60.9% | -20.0% | 61.2% | -1.2% | 26.4% | 28.5% | -4.6% | -13.6% | -6.3% | -14.6% | |
| Total Assets | 8.3% | 115.1% | 12.1% | 18.8% | 0.8% | 372.5% | -26.3% | -9.6% | -45.2% | -42.4% | |
| Book Value / Share | -54.9% | 47.2% | 10.6% | -24.5% | -20.7% | 596.3% | -35.4% | -15.0% | -52.8% | -57.6% | |
| Debt | 0.0% | 0.0% | -98.8% | 8010.8% | -6.4% | 6.5% | -19.3% | 8.5% | -2.5% | -7.6% | |
| Diluted Shares | 18.8% | 32.4% | 64.6% | 13.7% | 38.1% | 73.8% | -7.8% | 3.2% | 0.6% | 6.5% |
Valuation
P/E (TTM)At Loss
P/S23.61
10Y Low / Med / High3.85 / 12.26 / 308.12
P/B1.94
10Y Low / Med / High2.57 / 3.87 / 16.57
EV/EBITDAAt Loss
EV/Revenue22.69
10Y Low / Med / High2.74 / 12.19 / 225.60
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$2.01
Cash / Share
$2.05
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -2.50 | -3.96 | -2.94 | -1.93 | -12.82 | 399.02 | -5.49 | -10.31 | -2.48 | -1.49 | -0.42 | |
| P/S Ratio | 238.60 | 49.95 | 3.85 | 12.26 | 12.09 | 10.43 | 308.12 | 6.64 | 80.07 | 7.21 | 23.61 | |
| P/B Ratio | 13.50 | 9.17 | 3.87 | 6.95 | 16.57 | 3.61 | 2.85 | 2.57 | 3.06 | 2.81 | 1.94 | |
| EV/EBITDA | -2.44 | -4.11 | -2.23 | -2.68 | -14.61 | 146.66 | -4.13 | -8.34 | -2.08 | -1.32 | -0.63 | |
| EV/Revenue | 225.60 | 46.85 | 2.74 | 12.19 | 12.10 | 9.82 | 218.68 | 4.50 | 62.93 | 5.90 | 22.69 |
Analyst Estimates & Quality
Altman Z-Score
-29.75
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $2.0M | $2.5M | $3.0M |
| Net Income | -$7.1M | -$2.2M | -$2.0M |
| EPS | $-5.85 | $-1.80 | $-1.68 |
| # Analysts (EPS) | 1 | 1 | 1 |
Revenue Segments
By Geography
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Europe | $369.0K | $628.0K | $125.0K | — | — | — |
| TotalMember | $6.1M | $15.6M | — | — | — | — |
| UNITED STATES | — | $15.0M | $174.0K | $10.8M | $484.0K | $2.2M |
| CANADA | — | — | — | $87.0K | — | $96.0K |
| ISRAEL | — | — | — | $5.0K | $31.0K | $1.0K |